SCHEMBL462758

SCHEMBL462758

COC(N)(OC)c1ccccc1

nearest known ligand 0.50

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
KCNN4 O15554 4/20 0.50
MAPK1 P28482 1/20 0.44
CES1 P23141 1/20 0.42
ALDH1A1 P00352 2/20 0.41
TAAR1 Q96RJ0 1/20 0.41
ALOX15 P16050 1/20 0.41
KIF11 P52732 1/20 0.39
CYP1A2 P05177 1/20 0.39
CYP2D6 P10635 1/20 0.39
MAPT P10636 1/20 0.38
KMT2A Q03164 1/20 0.38
TSHR P16473 2/20 0.38
CA4 P22748 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL7899276 0.97 KCNN4 (0.48) KCNN4MAPK1CES1ALDH1A1TAAR1
SCHEMBL1430201 0.79 KCNN4 (0.50) KCNN4MAPK1CES1ALDH1A1TAAR1
SCHEMBL3478682 0.77 MAPK1 (0.48) KCNN4MAPK1CES1ALDH1A1TAAR1
SCHEMBL2700899 0.77 MAPK1 (0.48) KCNN4MAPK1CES1ALDH1A1TAAR1
SCHEMBL9545629 0.75 KCNN4 (0.46) KCNN4MAPK1CES1ALDH1A1TAAR1
SCHEMBL16487248 0.73 KCNN4 (0.39) KCNN4MAPK1CES1TAAR1KIF11
SCHEMBL28820080 0.73 KCNN4 (0.30) KCNN4
SCHEMBL30183453 0.73 KCNN4 (0.44) KCNN4MAPK1CES1ALDH1A1TAAR1
SCHEMBL28401721 0.73 KCNN4 (0.44) KCNN4MAPK1ALDH1A1TAAR1ALOX15
SCHEMBL2065992 0.73 TAAR1 (0.52) KCNN4MAPK1CES1TAAR1KIF11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 366 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3543236-B1 METHOD FOR PREPARING AVIBACTAM INTERMEDIATE XINFA PHARMACEUTICAL CO LTD (CN) 2022-02-16 EP claimed
CN-107827817-B Method for synthesizing formamide derivative through molybdenum catalytic formylation reaction 湘潭大学 2020-03-13 CN claimed
WO-2019075984-A1 METHOD FOR PREPARING AVIBACTAM INTERMEDIATE 新发药业有限公司 2019-04-25 WO claimed
CN-103709161-B One-dimensional organic semiconductor nanowire with fluorescence and photoconduction dual response for organic amine gas as well as preparation method and application of nanowire CHINESE ACAD INST CHEMISTRY 2015-05-20 CN claimed
CN-103709161-A One-dimensional organic semiconductor nanowire with fluorescence and photoconduction dual response for organic amine gas as well as preparation method and application of nanowire CHINESE ACAD INST CHEMISTRY 2014-04-09 CN claimed
WO-2012033956-A1 COGNITION ENHANCING COMPOUNDS AND COMPOSITIONS, METHODS OF MAKING, AND METHODS OF TREATING MITHRIDION, INC. (US) 2012-03-15 WO claimed
JP-6025163-A None JP disclosed
EP-4731689-A1 METHOD FOR THE PRODUCTION OF THERMOPLASTIC POLYOXAZOLIDINONE Covestro Deutschland AG (DE) 2026-04-29 EP disclosed
US-20260062427-A1 Bicyclic Ureas As Kinase Inhibitors INCYTE CORP (US) 2026-03-05 US disclosed
US-20250387397-A1 SUBSTITUTED AMINO TRIAZOLOPYRIMIDINE AND AMINO TRIAZOLOPYRAZINE ADENOSINE RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITIONS AND THEIR USE MERCK SHARP & DOHME LLC (US) 2025-12-25 US disclosed
EP-3883576-B1 SUBSTITUTED AMINO TRIAZOLOPYRIMIDINE AND AMINO TRIAZOLOPYRAZINE ADENOSINE RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITIONS AND THEIR USE MERCK SHARP & DOHME LLC (US) 2025-12-17 EP disclosed
EP-4200353-B1 METHOD FOR THE PRODUCTION OF A THERMOPLASTIC POLYOXAZOLIDINONE COVESTRO DEUTSCHLAND AG (DE) 2025-11-19 EP disclosed
EP-4448605-B1 PROCESS FOR THE PRODUCTION OF A THERMOPLASTIC POLYOXAZOLIDINONE COVESTRO DEUTSCHLAND AG (DE) 2025-11-19 EP disclosed
US-4166816-A CYCLIZATION SMITHKLINE CORPORATION (US) 1979-09-04 US disclosed
US-4162250-A INTERMEDIATES FOR BACTERICIDES SMITHKLINE CORPORATION (US) 1979-07-24 US disclosed
US-4144333-A Monocyclic beta-lactams with antibacterial activity SMITHKLINE CORPORATION (US) 1979-03-13 US disclosed
US-4122262-A ANTIBACTERIAL SMITHKLINE CORPORATION (US) 1978-10-24 US disclosed
US-4103086-A 8-Oxo-4-thia-1-azabicyclo (4.2.0)-oct-2-ene derivatives SMITHKLINE CORPORATION (US) 1978-07-25 US disclosed
US-4089956-A 7-Acylamino-8-oxo-3-oxa-1-azabicyclo[4.2.0]octane-2-carboxylic acid derivatives and bactericidal compositions and use thereof SMITHKLINE CORPORATION (US) 1978-05-16 US disclosed
US-4072674-A FOR CEPHALOSPORIN CONGENERS SMITHKLINE CORPORATION (US) 1978-02-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260062427-A1 Bicyclic Ureas As Kinase Inhibitors OXSR1, NCOR1, NR0B1 KCNN4 2409/4885MAPK1 32/4885CES1 928/4885
US-20250387397-A1 SUBSTITUTED AMINO TRIAZOLOPYRIMIDINE AND AMINO TRIAZOLOPYRAZINE ADENOSINE RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITIONS AND THEIR USE ADORA2A, ADORA2B, ADORA1 KCNN4 758/4885MAPK1 3417/4885CES1 687/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.